Compare Stocks: AYTU, FBIO, NTRB, and VRCA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.12 +6.0%	$2.22	$1.65 ▼ $3.07	$22.75M	0.26	21,185 shs	54,647 shs
FBIO Fortress Biotech	$2.51	$2.93	$2.18 ▼ $4.53	$83.71M	1.19	299,800 shs	414,674 shs
NTRB Nutriband	$8.13 +6.3%	$4.20	$2.80 ▼ $8.63	$98.83M	2.03	72,320 shs	110,092 shs
VRCA Verrica Pharmaceuticals	$4.45 -4.3%	$5.18	$3.28 ▼ $9.82	$76.45M	1.49	90,080 shs	113,179 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	0.00%	+6.53%	-7.02%	-8.23%	-8.62%
FBIO Fortress Biotech	0.00%	-0.40%	-9.39%	-16.05%	-27.03%
NTRB Nutriband	0.00%	+16.81%	+112.83%	+180.34%	+17.49%
VRCA Verrica Pharmaceuticals	0.00%	-9.37%	-8.44%	-20.96%	+0.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.12 +6.0%	$2.22	$1.65 ▼ $3.07	$22.75M	0.26	21,185 shs	54,647 shs
FBIO Fortress Biotech	$2.51	$2.93	$2.18 ▼ $4.53	$83.71M	1.19	299,800 shs	414,674 shs
NTRB Nutriband	$8.13 +6.3%	$4.20	$2.80 ▼ $8.63	$98.83M	2.03	72,320 shs	110,092 shs
VRCA Verrica Pharmaceuticals	$4.45 -4.3%	$5.18	$3.28 ▼ $9.82	$76.45M	1.49	90,080 shs	113,179 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	0.00%	+6.53%	-7.02%	-8.23%	-8.62%
FBIO Fortress Biotech	0.00%	-0.40%	-9.39%	-16.05%	-27.03%
NTRB Nutriband	0.00%	+16.81%	+112.83%	+180.34%	+17.49%
VRCA Verrica Pharmaceuticals	0.00%	-9.37%	-8.44%	-20.96%	+0.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYTU Aytu BioPharma	2.25	Hold	$10.75	407.08% Upside
FBIO Fortress Biotech	2.25	Hold	$17.00	577.29% Upside
NTRB Nutriband	1.50	Reduce	N/A	N/A
VRCA Verrica Pharmaceuticals	2.40	Hold	$12.67	184.64% Upside

Current Analyst Ratings Breakdown

Latest AYTU, FBIO, NTRB, and VRCA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	VRCA Verrica Pharmaceuticals	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
8/14/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/13/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/15/2026	VRCA Verrica Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/8/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
7/6/2026	AYTU Aytu BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/1/2026	NTRB Nutriband	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYTU Aytu BioPharma	$66.38M	0.34	$0.38 per share	5.65	$2.11 per share	1.00
FBIO Fortress Biotech	$63.26M	1.32	N/A	N/A	$2.00 per share	1.26
NTRB Nutriband	$2.04M	48.46	N/A	N/A	$0.44 per share	18.48
VRCA Verrica Pharmaceuticals	$35.58M	2.15	N/A	N/A	$1.55 per share	2.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYTU Aytu BioPharma	-$13.56M	-$4.58	N/A	8.48	N/A	-60.17%	-69.93%	-13.25%	9/29/2026 (Estimated)
FBIO Fortress Biotech	$6.82M	$2.64	0.95	N/A	N/A	163.32%	83.47%	42.98%	11/16/2026 (Estimated)
NTRB Nutriband	-$8.23M	-$0.53	N/A	N/A	N/A	-430.35%	-109.07%	-95.54%	9/30/2026 (Estimated)
VRCA Verrica Pharmaceuticals	-$17.89M	-$1.67	N/A	N/A	N/A	-102.84%	-407.11%	-70.17%	11/13/2026 (Estimated)

Latest AYTU, FBIO, NTRB, and VRCA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/29/2026	Q4 2026	AYTU Aytu BioPharma	-$0.29	N/A	N/A	N/A	$12.28 million	N/A
9/4/2026	Q2 2027	NTRB Nutriband	N/A	-$0.07	N/A	-$0.07	N/A	$0.44 million
8/13/2026	Q2 2026	FBIO Fortress Biotech	-$0.20	-$0.08	+$0.12	-$0.08	$18.30 million	$18.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYTU Aytu BioPharma	0.27	1.12	1.00
FBIO Fortress Biotech	0.17	3.96	3.83
NTRB Nutriband	N/A	4.21	4.02
VRCA Verrica Pharmaceuticals	0.18	1.45	1.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYTU Aytu BioPharma	33.49%
FBIO Fortress Biotech	96.51%
NTRB Nutriband	19.70%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
AYTU Aytu BioPharma	4.90%
FBIO Fortress Biotech	28.50%
NTRB Nutriband	52.21%
VRCA Verrica Pharmaceuticals	52.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYTU Aytu BioPharma	83	10.73 million	10.21 million	Not Optionable
FBIO Fortress Biotech	78	33.35 million	23.85 million	Optionable
NTRB Nutriband	3	12.16 million	5.81 million	Not Optionable
VRCA Verrica Pharmaceuticals	76	17.18 million	8.09 million	No Data

AYTU, FBIO, NTRB, and VRCA Headlines

Recent News About These Companies

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Hold" by Analysts

September 14, 2026 | marketbeat.com

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

September 10, 2026 | globenewswire.com

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | globenewswire.com

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data ...

August 27, 2026 | finance.yahoo.com

Lake Street Capital Begins Coverage on Verrica Pharmaceuticals (NASDAQ:VRCA)

August 27, 2026 | marketbeat.com

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

August 27, 2026 | globenewswire.com

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Buys 4,200 Shares

August 19, 2026 | insidertrades.com

Verrica (VRCA) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 6, 2026 | manilatimes.netM

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

August 6, 2026 | finance.yahoo.com

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026 | globenewswire.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum ...

July 21, 2026 | markets.businessinsider.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

July 21, 2026 | globenewswire.com

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment ...

June 23, 2026 | markets.businessinsider.com

Verrica Pharmaceuticals Announces First U.S. and Japanese Patients Dosed in Phase 3 COVE-3 Trial of YCANTH for Common Warts

June 22, 2026 | quiverquant.comQ

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

June 22, 2026 | globenewswire.com

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 28, 2026 | globenewswire.com

Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...

May 13, 2026 | uk.finance.yahoo.com

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

May 13, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU, FBIO, NTRB, and VRCA Company Descriptions

Aytu BioPharma NASDAQ:AYTU

$2.12 +0.12 (+6.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.12 0.00 (-0.24%)

As of 09/18/2026 07:30 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Fortress Biotech NASDAQ:FBIO

$2.51 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.58 +0.07 (+2.79%)

As of 09/18/2026 07:54 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Nutriband NASDAQ:NTRB

$8.13 +0.48 (+6.27%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$8.28 +0.15 (+1.89%)

As of 09/18/2026 07:37 PM Eastern

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Verrica Pharmaceuticals NASDAQ:VRCA

$4.45 -0.20 (-4.30%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.52 +0.07 (+1.57%)

As of 09/18/2026 07:30 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AYTU, FBIO, NTRB, and VRCA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AYTU, FBIO, NTRB, and VRCA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AYTU, FBIO, NTRB, and VRCA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU, FBIO, NTRB, and VRCA Company Descriptions

Aytu BioPharma NASDAQ:AYTU

Fortress Biotech NASDAQ:FBIO

Nutriband NASDAQ:NTRB

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AYTU, FBIO, NTRB, and VRCA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AYTU, FBIO, NTRB, and VRCA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AYTU, FBIO, NTRB, and VRCA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU, FBIO, NTRB, and VRCA Company Descriptions

Aytu BioPharma NASDAQ:AYTU

Fortress Biotech NASDAQ:FBIO

Nutriband NASDAQ:NTRB

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools